Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity (original) (raw)

Immunometabolism as therapeutic target

Dimethyl fumarate (DMF) is an immunomodulatory compound used to treat multiple sclerosis and psoriasis whose mechanisms of action remain only partially understood. Kornberg et al. found that DMF and its metabolite, monomethyl fumarate, succinate the glycolytic enzyme GAPDH (see the Perspective by Matsushita and Pearce). After DMF treatment, GAPDH was inactivated, and aerobic glycolysis was down-regulated in both myeloid and lymphoid cells. This resulted in down-modulated immune responses because inflammatory immune-cell subsets require aerobic glycolysis. Thus, metabolism can serve as a viable therapeutic target in autoimmune disease.

Science, this issue p. 449; see also p. 377

Abstract

Activated immune cells undergo a metabolic switch to aerobic glycolysis akin to the Warburg effect, thereby presenting a potential therapeutic target in autoimmune disease. Dimethyl fumarate (DMF), a derivative of the Krebs cycle intermediate fumarate, is an immunomodulatory drug used to treat multiple sclerosis and psoriasis. Although its therapeutic mechanism remains uncertain, DMF covalently modifies cysteine residues in a process termed succination. We found that DMF succinates and inactivates the catalytic cysteine of the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in mice and humans, both in vitro and in vivo. It thereby down-regulates aerobic glycolysis in activated myeloid and lymphoid cells, which mediates its anti-inflammatory effects. Our results provide mechanistic insight into immune modulation by DMF and represent a proof of concept that aerobic glycolysis is a therapeutic target in autoimmunity.

Register and access this article for free

As a service to the community, this article is available for free.

Access the full article

View all access options to continue reading this article.

Supplementary Material

Summary

Materials and Methods

Table S1

Figs. S1 to S15

References (30–38)

Resources

File (aan4665_kornberg_sm.pdf)

Download
1.87 MB

References and Notes

E. L. Pearce, E. J. Pearce, Metabolic pathways in immune cell activation and quiescence. Immunity 38, 633–643 (2013).

B. Kelly, L. A. O’Neill, Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res. 25, 771–784 (2015).

G. M. Tannahill, A. M. Curtis, J. Adamik, E. M. Palsson-McDermott, A. F. McGettrick, G. Goel, C. Frezza, N. J. Bernard, B. Kelly, N. H. Foley, L. Zheng, A. Gardet, Z. Tong, S. S. Jany, S. C. Corr, M. Haneklaus, B. E. Caffrey, K. Pierce, S. Walmsley, F. C. Beasley, E. Cummins, V. Nizet, M. Whyte, C. T. Taylor, H. Lin, S. L. Masters, E. Gottlieb, V. P. Kelly, C. Clish, P. E. Auron, R. J. Xavier, L. A. J. O’Neill, Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature 496, 238–242 (2013).

C. M. Cham, T. F. Gajewski, Glucose availability regulates IFN-γ production and p70S6 kinase activation in CD8+ effector T cells. J. Immunol. 174, 4670–4677 (2005).

C. M. Cham, G. Driessens, J. P. O’Keefe, T. F. Gajewski, Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells. Eur. J. Immunol. 38, 2438–2450 (2008).

R. Wang, C. P. Dillon, L. Z. Shi, S. Milasta, R. Carter, D. Finkelstein, L. L. McCormick, P. Fitzgerald, H. Chi, J. Munger, D. R. Green, The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35, 871–882 (2011).

A. N. Macintyre, V. A. Gerriets, A. G. Nichols, R. D. Michalek, M. C. Rudolph, D. Deoliveira, S. M. Anderson, E. D. Abel, B. J. Chen, L. P. Hale, J. C. Rathmell, The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 20, 61–72 (2014).

V. A. Gerriets, R. J. Kishton, A. G. Nichols, A. N. Macintyre, M. Inoue, O. Ilkayeva, P. S. Winter, X. Liu, B. Priyadharshini, M. E. Slawinska, L. Haeberli, C. Huck, L. A. Turka, K. C. Wood, L. P. Hale, P. A. Smith, M. A. Schneider, N. J. MacIver, J. W. Locasale, C. B. Newgard, M. L. Shinohara, J. C. Rathmell, Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation. J. Clin. Invest. 125, 194–207 (2015).

C. H. Chang, J. D. Curtis, L. B. Maggi Jr., B. Faubert, A. V. Villarino, D. O’Sullivan, S. C.-C. Huang, G. J. W. van der Windt, J. Blagih, J. Qiu, J. D. Weber, E. J. Pearce, R. G. Jones, E. L. Pearce, Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153, 1239–1251 (2013).

D. Vats, L. Mukundan, J. I. Odegaard, L. Zhang, K. L. Smith, C. R. Morel, R. A. Wagner, D. R. Greaves, P. J. Murray, A. Chawla, Oxidative metabolism and PGC-1β attenuate macrophage-mediated inflammation. Cell Metab. 4, 13–24 (2006).

L. Z. Shi, R. Wang, G. Huang, P. Vogel, G. Neale, D. R. Green, H. Chi, HIF1α-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 208, 1367–1376 (2011).

R. A. Linker, A. Haghikia, Dimethyl fumarate in multiple sclerosis: Latest developments, evidence and place in therapy. Ther. Adv. Chronic Dis. 7, 198–207 (2016).

R. A. Linker, D.-H. Lee, S. Ryan, A. M. van Dam, R. Conrad, P. Bista, W. Zeng, X. Hronowsky, A. Buko, S. Chollate, G. Ellrichmann, W. Brück, K. Dawson, S. Goelz, S. Wiese, R. H. Scannevin, M. Lukashev, R. Gold, Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134, 678–692 (2011).

M. M. Blewett, J. Xie, B. W. Zaro, K. M. Backus, A. Altman, J. R. Teijaro, B. F. Cravatt, Chemical proteomic map of dimethyl fumarate-sensitive cysteines in primary human T cells. Sci. Signal. 9, rs10 (2016).

U. Schulze-Topphoff, M. Varrin-Doyer, K. Pekarek, C. M. Spencer, A. Shetty, S. A. Sagan, B. A. C. Cree, R. A. Sobel, B. T. Wipke, L. Steinman, R. H. Scannevin, S. S. Zamvil, Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc. Natl. Acad. Sci. U.S.A. 113, 4777–4782 (2016).

M. Blatnik, N. Frizzell, S. R. Thorpe, J. W. Baynes, Inactivation of glyceraldehyde-3-phosphate dehydrogenase by fumarate in diabetes: Formation of S-(2-succinyl)cysteine, a novel chemical modification of protein and possible biomarker of mitochondrial stress. Diabetes 57, 41–49 (2008).

N. H. Litjens, J. Burggraaf, E. van Strijen, C. van Gulpen, H. Mattie, R. C. Schoemaker, J. T. van Dissel, H. B. Thio, P. H. Nibbering, Pharmacokinetics of oral fumarates in healthy subjects. Br. J. Clin. Pharmacol. 58, 429–432 (2004).

M. Rostami-Yazdi, B. Clement, T. J. Schmidt, D. Schinor, U. Mrowietz, Detection of metabolites of fumaric acid esters in human urine: Implications for their mode of action. J. Invest. Dermatol. 129, 231–234 (2009).

H. Peng, H. Li, A. Sheehy, P. Cullen, N. Allaire, R. H. Scannevin, Dimethyl fumarate alters microglia phenotype and protects neurons against proinflammatory toxic microenvironments. J. Neuroimmunol. 299, 35–44 (2016).

Z. D. Parsons, K. S. Gates, Redox regulation of protein tyrosine phosphatases: Methods for kinetic analysis of covalent enzyme inactivation. Methods Enzymol. 528, 129–154 (2013).

N. Kamada, S. U. Seo, G. Y. Chen, G. Núñez, Role of the gut microbiota in immunity and inflammatory disease. Nat. Rev. Immunol. 13, 321–335 (2013).

A. A. Shestov, X. Liu, Z. Ser, A. A. Cluntun, Y. P. Hung, L. Huang, D. Kim, A. Le, G. Yellen, J. G. Albeck, J. W. Locasale, Quantitative determinants of aerobic glycolysis identify flux through the enzyme GAPDH as a limiting step. eLife 3, 03342 (2014).

M. V. Liberti, Z. Dai, S. E. Wardell, J. A. Baccile, X. Liu, X. Gao, R. Baldi, M. Mehrmohamadi, M. O. Johnson, N. S. Madhukar, A. A. Shestov, I. I. C. Chio, O. Elemento, J. C. Rathmell, F. C. Schroeder, D. P. McDonnell, J. W. Locasale, A predictive model for selective targeting of the Warburg effect through GAPDH inhibition with a natural product. Cell Metab. 26, 648–659.e8 (2017).

J. Yun, E. Mullarky, C. Lu, K. N. Bosch, A. Kavalier, K. Rivera, J. Roper, I. I. C. Chio, E. G. Giannopoulou, C. Rago, A. Muley, J. M. Asara, J. Paik, O. Elemento, Z. Chen, D. J. Pappin, L. E. Dow, N. Papadopoulos, S. S. Gross, L. C. Cantley, Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 350, 1391–1396 (2015).

M. A. Michell-Robinson, C. S. Moore, L. M. Healy, L. A. Osso, N. Zorko, V. Grouza, H. Touil, L. Poliquin-Lasnier, A.-M. Trudelle, P. S. Giacomini, A. Bar-Or, J. P. Antel, Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis. Ann. Clin. Transl. Neurol. 3, 27–41 (2015).

K. Sakai, K. Hasumi, A. Endo, Identification of koningic acid (heptelidic acid)-modified site in rabbit muscle glyceraldehyde-3-phosphate dehydrogenase. Biochim. Biophys. Acta 1077, 192–196 (1991).

E. Nagy, W. F. Rigby, Glyceraldehyde-3-phosphate dehydrogenase selectively binds AU-rich RNA in the NAD+-binding region (Rossmann fold). J. Biol. Chem. 270, 2755–2763 (1995).

C. M. Spencer, E. C. Crabtree-Hartman, K. Lehmann-Horn, B. A. Cree, S. S. Zamvil, Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol. Neuroimmunol. Neuroinflamm. 2, e76 (2015).

C. C. Gross, A. Schulte-Mecklenbeck, S. Klinsing, A. Posevitz-Fejfár, H. Wiendl, L. Klotz, Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 3, e183 (2015).

M. R. Hara, N. Agrawal, S. F. Kim, M. B. Cascio, M. Fujimuro, Y. Ozeki, M. Takahashi, J. H. Cheah, S. K. Tankou, L. D. Hester, C. D. Ferris, S. D. Hayward, S. H. Snyder, A. Sawa, S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. Nat. Cell Biol. 7, 665–674 (2005).

P. A. Calabresi, R. Allie, K. M. Mullen, S. H. Yun, R. W. Georgantas 3rd, K. A. Whartenby, Kinetics of CCR7 expression differ between primary activation and effector memory states of TH1 and TH2 cells. J. Neuroimmunol. 139, 58–65 (2003).

A. Shevchenko, O. N. Jensen, A. V. Podtelejnikov, F. Sagliocco, M. Wilm, O. Vorm, P. Mortensen, A. Shevchenko, H. Boucherie, M. Mann, Linking genome and proteome by mass spectrometry: Large-scale identification of yeast proteins from two dimensional gels. Proc. Natl. Acad. Sci. U.S.A. 93, 14440–14445 (1996).

A. Keller, A. I. Nesvizhskii, E. Kolker, R. Aebersold, Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 74, 5383–5392 (2002).

A. I. Nesvizhskii, A. Keller, E. Kolker, R. Aebersold, A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 75, 4646–4658 (2003).

G. J. van der Windt, C. H. Chang, E. L. Pearce. Measuring bioenergetics in T cells using a Seahorse extracellular flux analyzer. Curr. Protoc. Immunol. 113, 16B.1-16B.14 (2016).

V. Vantaku, S. R. Donepudi, C. R. Ambati, F. Jin, V. Putluri, K. Nguyen, K. Rajapakshe, C. Coarfa, V. L. Battula, Y. Lotan, N. Putluri, Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer. Oncotarget 8, 95620–95631 (2017).

F. Jin, J. Thaiparambil, S. R. Donepudi, V. Vantaku, D. W. B. Piyarathna, S. Maity, R. Krishnapuram, V. Putluri, F. Gu, P. Purwaha, S. K. Bhowmik, C. R. Ambati, F.-C. von Rundstedt, F. Roghmann, S. Berg, J. Noldus, K. Rajapakshe, D. Gödde, S. Roth, S. Störkel, S. Degener, G. Michailidis, B. A. Kaipparettu, B. Karanam, M. K. Terris, S. M. Kavuri, S. P. Lerner, F. Kheradmand, C. Coarfa, A. Sreekumar, Y. Lotan, R. El-Zein, N. Putluri, Tobacco-specific carcinogens induce hypermethylation, DNA adducts, and DNA damage in bladder cancer. Cancer Prev. Res. 10, 588–597 (2017).

D. W. B. Piyarathna, T. M. Rajendiran, V. Putluri, V. Vantaku, T. Soni, F. C. von Rundstedt, S. R. Donepudi, F. Jin, S. Maity, C. R. Ambati, J. Dong, D. Gödde, S. Roth, S. Störkel, S. Degener, G. Michailidis, S. P. Lerner, S. Pennathur, Y. Lotan, C. Coarfa, A. Sreekumar, N. Putluri, Distinct lipidomic landscapes associated with clinical stages of urothelial cancer of the bladder. Eur. Urol. Focus 17, 30107–30114 (2017).